DE69832513D1 - Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste - Google Patents

Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste

Info

Publication number
DE69832513D1
DE69832513D1 DE69832513T DE69832513T DE69832513D1 DE 69832513 D1 DE69832513 D1 DE 69832513D1 DE 69832513 T DE69832513 T DE 69832513T DE 69832513 T DE69832513 T DE 69832513T DE 69832513 D1 DE69832513 D1 DE 69832513D1
Authority
DE
Germany
Prior art keywords
agoniste
prostaglandines
aromatic
substituted tetrahydro
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832513T
Other languages
English (en)
Other versions
DE69832513T2 (de
Inventor
August Wos
Anthony Delong
S Amburgey
Biswanath De
George Dai
J Miley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Durham
Duke University
Original Assignee
University of Durham
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Durham, Duke University filed Critical University of Durham
Publication of DE69832513D1 publication Critical patent/DE69832513D1/de
Application granted granted Critical
Publication of DE69832513T2 publication Critical patent/DE69832513T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE69832513T 1997-09-09 1998-09-04 Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste Expired - Lifetime DE69832513T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5824697P 1997-09-09 1997-09-09
US58246P 1997-09-09
PCT/US1998/018340 WO1999012896A1 (en) 1997-09-09 1998-09-04 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists

Publications (2)

Publication Number Publication Date
DE69832513D1 true DE69832513D1 (de) 2005-12-29
DE69832513T2 DE69832513T2 (de) 2006-07-13

Family

ID=22015602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832513T Expired - Lifetime DE69832513T2 (de) 1997-09-09 1998-09-04 Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste

Country Status (23)

Country Link
US (1) US6107338A (de)
EP (1) EP1021402B1 (de)
JP (1) JP2001515883A (de)
KR (1) KR20010023837A (de)
CN (1) CN1269785A (de)
AR (1) AR017077A1 (de)
AT (1) ATE310721T1 (de)
AU (1) AU741014B2 (de)
BR (1) BR9811779A (de)
CA (1) CA2303763C (de)
CO (1) CO4970730A1 (de)
DE (1) DE69832513T2 (de)
ES (1) ES2253826T3 (de)
HU (1) HUP0004436A3 (de)
IL (1) IL134792A0 (de)
NO (1) NO20001142L (de)
NZ (1) NZ503736A (de)
PE (1) PE123199A1 (de)
PL (1) PL339213A1 (de)
SK (1) SK3362000A3 (de)
TR (1) TR200000670T2 (de)
WO (1) WO1999012896A1 (de)
ZA (1) ZA988231B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015608A1 (en) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
ES2232434T3 (es) * 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
EP1202999B1 (de) * 1999-08-04 2003-06-18 The Procter & Gamble Company Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6586462B2 (en) 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US7631336B2 (en) 2004-07-30 2009-12-08 Broadband Itv, Inc. Method for converting, navigating and displaying video content uploaded from the internet to a digital TV video-on-demand platform
US7590997B2 (en) 2004-07-30 2009-09-15 Broadband Itv, Inc. System and method for managing, converting and displaying video content on a video-on-demand platform, including ads used for drill-down navigation and consumer-generated classified ads
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3053913B1 (de) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
CA2850987C (en) 2011-10-17 2019-10-15 Biotheryx, Inc. Substituted biaryl alkyl amides
CN109528721B (zh) 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
CN104140410B (zh) * 2013-05-09 2017-12-15 江苏豪森药业集团有限公司 鲁比前列酮的制备方法
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CA3035566A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
IL43571A (en) * 1972-11-08 1977-08-31 Pfizer Omega-pentanorprostaglandins and their preparation
JPS5720305B2 (de) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
AU5258698A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
AU725677B2 (en) * 1997-05-09 2000-10-19 Mount Sinai School Of Medicine Of The City University Of New York, The 8-iso-prostaglandins for glaucoma therapy

Also Published As

Publication number Publication date
AU9219498A (en) 1999-03-29
CA2303763A1 (en) 1999-03-18
EP1021402B1 (de) 2005-11-23
ES2253826T3 (es) 2006-06-01
IL134792A0 (en) 2001-04-30
WO1999012896A1 (en) 1999-03-18
DE69832513T2 (de) 2006-07-13
NZ503736A (en) 2002-06-28
SK3362000A3 (en) 2000-10-09
CO4970730A1 (es) 2000-11-07
ZA988231B (en) 1999-03-09
TR200000670T2 (tr) 2000-11-21
NO20001142L (no) 2000-05-04
HUP0004436A3 (en) 2001-09-28
EP1021402A1 (de) 2000-07-26
US6107338A (en) 2000-08-22
KR20010023837A (ko) 2001-03-26
BR9811779A (pt) 2000-09-12
CN1269785A (zh) 2000-10-11
ATE310721T1 (de) 2005-12-15
AR017077A1 (es) 2001-08-22
AU741014B2 (en) 2001-11-22
PE123199A1 (es) 2000-02-02
CA2303763C (en) 2007-04-24
PL339213A1 (en) 2000-12-04
JP2001515883A (ja) 2001-09-25
NO20001142D0 (no) 2000-03-06
HUP0004436A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
DE69832513D1 (de) Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste
DE69824966D1 (de) Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste
DE69816441D1 (de) Schalteranordnung
DE69810183D1 (de) Schalteranordnung
DE69908076D1 (de) Schalteranordnung
DE59803277D1 (de) Schalter
DE29704875U1 (de) Joystick-Anordnung
DE69814207D1 (de) Schalterkombination
DE60034297D1 (de) Schalteranordnung
DE29704758U1 (de) Hydraulische Schalteinheit
DE29821667U1 (de) Aufzug
DE29704886U1 (de) Aufzug
DE59808470D1 (de) Matrixschalter
DE10084736T1 (de) Schalterkonstruktion
DE29709759U1 (de) Schalteinheit
FI974049A0 (fi) Omkopplare
KR970060372U (ko) 쿠션이 있는 신발굽 구조
DE69813719T2 (de) Schalter
DE29717428U1 (de) Zwischensohlen-Struktur
DE29711163U1 (de) Sicherheitsschalter
ES1040845Y (es) Estructura de hueco de ascensor.
DE29722021U1 (de) Sicherheitsschalter
ID20763A (id) Mesin tenun
KR970052747U (ko) 풋스위치
DE29702815U1 (de) Umschalter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition